Loading clinical trials...
Loading clinical trials...
SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor
Conditions
Interventions
Rucaparib
Lucitanib
+1 more
Locations
3
United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
June 28, 2019
Primary Completion Date
March 8, 2022
Completion Date
April 22, 2022
Last Updated
January 16, 2024
NCT05889195
NCT06393374
NCT03050268
NCT06257264
NCT06964009
NCT05491226
Lead Sponsor
pharmaand GmbH
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions